Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives $51.14 Average Target Price from Analysts

Scholar Rock Holding Corporation (NASDAQ:SRRK) has earned a consensus rating of “Buy” from the seventeen research firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, twelve have issued a buy recommendation and four have given a strong buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $54.1429.

Several research firms recently commented on SRRK. Wolfe Research began coverage on Scholar Rock in a research note on Tuesday, November 18th. They issued an “outperform” rating and a $42.00 target price for the company. Barclays upped their price objective on shares of Scholar Rock from $52.00 to $53.00 and gave the company an “overweight” rating in a research note on Tuesday. Raymond James Financial reissued a “strong-buy” rating on shares of Scholar Rock in a research report on Tuesday. UBS Group initiated coverage on shares of Scholar Rock in a research report on Wednesday, January 7th. They set a “buy” rating and a $60.00 price target for the company. Finally, BMO Capital Markets lifted their price target on shares of Scholar Rock from $50.00 to $70.00 and gave the company an “outperform” rating in a report on Wednesday.

Scholar Rock Stock Performance

Shares of SRRK opened at $47.43 on Thursday. The company has a market capitalization of $4.84 billion, a price-to-earnings ratio of -13.83 and a beta of 0.70. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.30 and a current ratio of 6.30. Scholar Rock has a 1 year low of $22.71 and a 1 year high of $49.82. The company’s 50 day simple moving average is $45.32 and its 200 day simple moving average is $39.14.

Scholar Rock (NASDAQ:SRRK) last issued its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.86) by $0.10. During the same period last year, the company earned ($0.64) earnings per share. On average, sell-side analysts predict that Scholar Rock will post -2.42 EPS for the current year.

Insider Transactions at Scholar Rock

In other news, insider Caryn Parlavecchio sold 9,035 shares of the business’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $46.53, for a total transaction of $420,398.55. Following the completion of the sale, the insider owned 169,087 shares in the company, valued at approximately $7,867,618.11. The trade was a 5.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel Junlin Ho sold 9,580 shares of the stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $46.53, for a total transaction of $445,757.40. Following the sale, the general counsel directly owned 241,545 shares of the company’s stock, valued at approximately $11,239,088.85. This trade represents a 3.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 208,470 shares of company stock worth $9,201,778 in the last three months. 13.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Scholar Rock

Several large investors have recently made changes to their positions in the business. Siren L.L.C. raised its stake in shares of Scholar Rock by 17.0% in the 4th quarter. Siren L.L.C. now owns 10,825,013 shares of the company’s stock valued at $476,842,000 after acquiring an additional 1,575,008 shares during the period. Wellington Management Group LLP raised its position in Scholar Rock by 26.7% in the fourth quarter. Wellington Management Group LLP now owns 5,759,428 shares of the company’s stock valued at $253,703,000 after purchasing an additional 1,213,541 shares during the period. Vanguard Group Inc. lifted its stake in shares of Scholar Rock by 5.7% during the fourth quarter. Vanguard Group Inc. now owns 5,195,465 shares of the company’s stock worth $228,860,000 after purchasing an additional 280,538 shares in the last quarter. State Street Corp boosted its position in shares of Scholar Rock by 7.2% in the fourth quarter. State Street Corp now owns 4,034,434 shares of the company’s stock worth $177,717,000 after buying an additional 271,331 shares during the period. Finally, Orbis Allan Gray Ltd grew its stake in shares of Scholar Rock by 1,034.5% in the fourth quarter. Orbis Allan Gray Ltd now owns 3,428,929 shares of the company’s stock valued at $151,044,000 after buying an additional 3,126,677 shares in the last quarter. Institutional investors and hedge funds own 91.08% of the company’s stock.

Key Headlines Impacting Scholar Rock

Here are the key news stories impacting Scholar Rock this week:

• Positive Sentiment: Scholar Rock outlined a 2026 plan to resubmit the BLA for apitegromab and pursue a commercial launch following recent FDA progress — a clear pipeline/come-to-market catalyst for the stock. Seeking Alpha: Apitegromab BLA update
• Positive Sentiment: BMO Capital Markets increased its price target from $50 to $70 and kept an “outperform” rating — the largest PT bump among recent analyst moves and a material upside signal to investors. Benzinga: BMO raise
• Positive Sentiment: Citigroup raised its price target to $58 and maintained a “buy” rating, reinforcing analyst conviction after the FDA/regulatory update. Benzinga: Citigroup raise
• Positive Sentiment: Piper Sandler raised its target to $58 and kept an “overweight” rating, adding to the cluster of bullish analyst revisions. Street Insider: Piper Sandler note
• Positive Sentiment: HC Wainwright reaffirmed a “buy” rating with a $58 target, another vote of confidence from the sell-side. American Banking News: HC Wainwright
• Positive Sentiment: Scholar Rock’s corrected Q4 release shows net loss per share of $0.76 (correcting an earlier $0.88 figure) and the company narrowly beat EPS consensus — supporting near-term sentiment. Business Wire: Q4 results correction
• Neutral Sentiment: Full earnings and management commentary are available in the Q4 2025 call transcripts (useful for modeling but not introducing new surprises). Seeking Alpha: Q4 earnings transcript InsiderMonkey transcript

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).